These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 34115243)

  • 1. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
    Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
    Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment options for HER2-positive breast cancer patients with brain metastases.
    Galanti D; Inno A; La Vecchia M; Borsellino N; Incorvaia L; Russo A; Gori S
    Crit Rev Oncol Hematol; 2021 May; 161():103329. PubMed ID: 33862249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
    Kimmick G; Dent S; Klem I
    Curr Treat Options Cardiovasc Med; 2019 May; 21(6):30. PubMed ID: 31152324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
    Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
    Waliany S; Caswell-Jin J; Riaz F; Myall N; Zhu H; Witteles RM; Neal JW
    JACC CardioOncol; 2023 Feb; 5(1):85-98. PubMed ID: 36875913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
    Andersson AE; Linderholm B; Giglio D
    Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
    J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy.
    Alowais SA; Luk SO; Kim EB; Alsuhebany N; Zangardi M
    J Oncol Pharm Pract; 2024 Sep; 30(6):992-998. PubMed ID: 37528623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.